GA-SYNCRON
27.9.2021 15:04:10 CEST | Business Wire | Press release
Syncron, the largest privately-owned global leader in intelligent SaaS solutions dedicated to End-to-End Continuous Service LifeCycle Management, announced today that it has been named a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment (doc # US46742021, September 2021). Syncron is providing a complimentary excerpt of the IDC MarketScape report here .
The IDC MarketScape vendor assessment model is an important competitive evaluation and scoring of the SaaS-based business-to-business price optimization and management solution suppliers available in the global market. According to the IDC MarketScape the nine vendors covered in the IDC MarketScape represent the front-runners and the vendors most representative of any given B2B PO&M application buyer's selection short list. IDC’s research methodology uses a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear, customer influenced framework, in which the product and service offerings, capabilities, and strategies, and current and future market success factors can be meaningfully compared.
The IDC MarketScape report’s profile stated, “After a thorough evaluation of Syncron's offerings and capabilities, IDC has positioned the company in the Leaders category within this 2021 IDC MarketScape for B2B price optimization and management applications.” The report also states that “Syncron has greatly expanded its vision to be the end-to-end service management provider. This is an integrated suite of solutions to optimize inventory, price, and uptime for aftermarket parts and service for B2B or retail-focused companies. This enables Syncron to optimize both price and cost.”
The research positioned Syncron as a leader based on the flexible capabilities and intuitive functionality of Syncron Price, and the company’s deep understanding of the aftermarket industry globally.
The report states that companies should consider Syncron when they’re in the aftermarket service industry and need an end-to-end service management solution with integrated pricing. The IDC MarketScape vendor assessment also recognized three of Syncron’s strengths:
Deep understanding of aftermarket service management: Syncron Price benefits from Syncron Inventory and the company's deep institutional knowledge of the cost side of the equation to manage profit when pricing inventory that is deployed around the world, including location (delivery time, taxes, tariffs), age, and scarcity/replacement value. Customers highly appreciated this experience to set up personalized pricing for specialty parts and kits.
Ease of Use: Customers highly rated Syncron for how easy the product was to learn and use. They liked that it had initiative workflows that were "one to two clicks away from done."
Pricing Agility: Syncron makes it easy to segment and manage huge numbers of parts. Customers liked the ML-driven segmentation workflow that made segmentation easy to implement and gave the user the best choices of which segment the product should be placed in. One customer was managing 300,000 parts with one person while being able to reprice each on a far more regular basis with greater profit.
“Syncron combines its deep knowledge of the global aftermarket industries, with robust solution capabilities, and expert services to substantively increase the efficiency and profitability of an OEM's aftermarket businesses,” says Mark Thomason, Research Director, IDC. “Syncron Price enables manufacturers, dealers, and suppliers to automate and optimize dynamic pricing capabilities, quickly and globally. By leveraging artificial intelligence and machine learning, Syncron Price can segment highly complex product lists and identify otherwise unseen revenue uplift and margin opportunities.”
“At Syncron, we’re committed to empower the world’s leading manufacturers and distributors to drive profitable business and competitive advantage by providing intelligent and connected service experience solutions. We are deeply honored the IDC MarketScape named Syncron a Leader for the Price Optimization and Management category. This acknowledgement follows similar IDC MarketScape recognitions of Syncron and its newly acquired company, Mize, in the areas of Field Service Management (FSM)1 , Service Parts Management (SPM), and Warranty Contract Management (WCM)2 ,” said Dr. Friedrich Neumeyer, CEO of Syncron. “Being recognized as a leader in multiple strategic categories by the IDC MarketScape is validation that our significant innovation investments in AI and ML innovation, user experience, architectural extensibility, scalability, security, and platform are quickly paying dividends. It also echoes Syncron’s nonstop passion and commitment and ability to execute our customers’ success.”
To learn more about Syncron Price, www.syncron.com/price .
About Syncron
Syncron accelerates leading manufacturers and distributors to capitalize on the world's new service economy. We improve aftermarket business profitability, optimize working capital, increase customer loyalty, and enable our customer’s ability to transition successfully to future service-driven business models. With our industry-leading investments in AI and ML, Syncron offers the first, innovative, customer-endorsed, and complete end-to-end intelligent Service Lifecycle Management solution portfolio. Syncron’s offer encompasses leadership solutions such as: service parts inventory, price, equipment uptime, warranty, service contract, and field service management. Delivered on Syncron’s Connected Service Experience (CSX) platform, our solutions offer our customers competitive differentiation through exceptional aftermarket service experiences, while simultaneously driving significant revenue and profit improvements into a manufacturer or distributor’s business. It is no secret that world's top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more information, visit syncron.com .
1 IDC MarketScape: Worldwide Manufacturing Field Service Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC #US44408719, November 2019
2 IDC MarketScape: Worldwide Manufacturing Warranty and Service Contract Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC# US44408619 December 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
